Your browser doesn't support javascript.
loading
Distribution and genotype-phenotype correlation of GDAP1 mutations in Spain.
Sivera, Rafael; Frasquet, Marina; Lupo, Vincenzo; García-Sobrino, Tania; Blanco-Arias, Patricia; Pardo, Julio; Fernández-Torrón, Roberto; de Munain, Adolfo López; Márquez-Infante, Celedonio; Villarreal, Liliana; Carbonell, Pilar; Rojas-García, Ricard; Segovia, Sonia; Illa, Isabel; Frongia, Anna Lia; Nascimento, Andrés; Ortez, Carlos; García-Romero, María Del Mar; Pascual, Samuel Ignacio; Pelayo-Negro, Ana Lara; Berciano, José; Guerrero, Antonio; Casasnovas, Carlos; Camacho, Ana; Esteban, Jesús; Chumillas, María José; Barreiro, Marisa; Díaz, Carmen; Palau, Francesc; Vílchez, Juan Jesús; Espinós, Carmen; Sevilla, Teresa.
  • Sivera R; Department of Neurology, Hospital Francesc de Borja, Gandía, Spain. rafasivera@gmail.com.
  • Frasquet M; Department of Neurology, Hospital Universitari i Politécnic La Fe, Valencia, Spain.
  • Lupo V; Neuromuscular Research Unit, Instituto de Investigación Sanitaria la Fe (IIS La Fe), Valencia, Spain.
  • García-Sobrino T; Unit of Genetics and Genomics of Neuromuscular and Neurodegenerative Disorders and Service of Genomics and Traslational Geneticis, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain.
  • Blanco-Arias P; Department of Neurology, Hospital Clínico, Santiago de Compostela, Spain.
  • Pardo J; Neurogenetics Research Group, Instituto de Investigaciones Sanitarias (IDIS), Santiago de Compostela, Spain.
  • Fernández-Torrón R; Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain.
  • de Munain AL; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Intituto Carlos III, Ministry of Economy and Competitiviness, Madrid, Spain.
  • Márquez-Infante C; Department of Neurology, Hospital Clínico, Santiago de Compostela, Spain.
  • Villarreal L; Neuromuscular Disorders Unit, Neurology Department, Hospital Donostia, San Sebastián, Spain.
  • Carbonell P; The John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
  • Rojas-García R; Neuroscience Area, Biodonostia Health Research Institute, San Sebastián, Spain.
  • Segovia S; Center for Biomedical Research in the Neurodegenerative Diseases (CIBERNED) Network, Instituto Carlos III, Ministry of Economy and Competitiviness, Madrid, Spain.
  • Illa I; Neuromuscular Disorders Unit, Neurology Department, Hospital Donostia, San Sebastián, Spain.
  • Frongia AL; Neuroscience Area, Biodonostia Health Research Institute, San Sebastián, Spain.
  • Nascimento A; Center for Biomedical Research in the Neurodegenerative Diseases (CIBERNED) Network, Instituto Carlos III, Ministry of Economy and Competitiviness, Madrid, Spain.
  • Ortez C; Department of Neurosciences, School of Medicine, University of the Basque Country (EHU-UPV), San Sebastián, Spain.
  • García-Romero MDM; Department of Neurology and Neurophysiology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Pascual SI; Department of Neurology and Neurophysiology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Pelayo-Negro AL; Department of Neurology and Neurophysiology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Berciano J; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Intituto Carlos III, Ministry of Economy and Competitiviness, Madrid, Spain.
  • Guerrero A; Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Casasnovas C; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Intituto Carlos III, Ministry of Economy and Competitiviness, Madrid, Spain.
  • Camacho A; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Intituto Carlos III, Ministry of Economy and Competitiviness, Madrid, Spain.
  • Esteban J; Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Chumillas MJ; Neuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Déu, Fundacion Sant Joan de Deu, Barcelona, Spain.
  • Barreiro M; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Intituto Carlos III, Ministry of Economy and Competitiviness, Madrid, Spain.
  • Díaz C; Neuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Déu, Fundacion Sant Joan de Deu, Barcelona, Spain.
  • Palau F; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Intituto Carlos III, Ministry of Economy and Competitiviness, Madrid, Spain.
  • Vílchez JJ; Neuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Déu, Fundacion Sant Joan de Deu, Barcelona, Spain.
  • Espinós C; Neuropaediatrics Department, Hospital la Paz, Madrid, Spain.
  • Sevilla T; Neuropaediatrics Department, Hospital la Paz, Madrid, Spain.
Sci Rep ; 7(1): 6677, 2017 07 27.
Article en En | MEDLINE | ID: mdl-28751717
ABSTRACT
Mutations in the GDAP1 gene can cause Charcot-Marie-Tooth disease. These mutations are quite rare in most Western countries but not so in certain regions of Spain or other Mediterranean countries. This cross-sectional retrospective multicenter study analyzed the clinical and genetic characteristics of patients with GDAP1 mutations across Spain. 99 patients were identified, which were distributed across most of Spain, but especially in the Northwest and Mediterranean regions. The most common genotypes were p.R120W (in 81% of patients with autosomal dominant inheritance) and p.Q163X (in 73% of autosomal recessive patients). Patients with recessively inherited mutations had a more severe phenotype, and certain clinical features, like dysphonia or respiratory dysfunction, were exclusively detected in this group. Dominantly inherited mutations had prominent clinical variability regarding severity, including 29% of patients who were asymptomatic. There were minor clinical differences between patients harboring specific mutations but not when grouped according to localization or type of mutation. This is the largest clinical series to date of patients with GDAP1 mutations, and it contributes to define the genetic distribution and genotype-phenotype correlation in this rare form of CMT.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Charcot-Marie-Tooth / Estudios de Asociación Genética / Mutación / Proteínas del Tejido Nervioso Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged País como asunto: Europa Idioma: En Año: 2017 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Charcot-Marie-Tooth / Estudios de Asociación Genética / Mutación / Proteínas del Tejido Nervioso Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged País como asunto: Europa Idioma: En Año: 2017 Tipo del documento: Article